Filtering

Page: () 1 ... 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 ... 182 ()
P131: Effectiveness and safety of vedolizumab maintenance therapy for inflammatory bowel disease: findings from a Belgian registry

ECCO '19 Copenhagen

Year: 2019
Authors:

E. Louis*1, V. Muls2, P. Bossuyt3, A. Colard4, A. Nakad5, D. Baert6, F. Mana7, P. Caenepeel8, S. Vanden Branden9, S. Vermeire10, F. D’Heygere11, B. Strubbe12, A. Cremer13, J-C. Coche14, V. Setakhr15, F. Baert16, A. Vijverman17, J. L. Coenegrachts18, F. Flamme19, A. Hantson20, K. Wijnen20, E. Piters20, G. Hantsbarger21, F. Wan21, B. Jiang21, P. Dolin22

1University Hospital CHU of Liège, Liege, Belgium, 2Saint-Pierre University Hospital,, Brussels, Belgium, 3Imeldaziekenhuis, Bonheiden, Belgium, 4Hospital CHC, Liège, Belgium, 5CHwapi Notre Dame, Tournai, Belgium, 6Maria Middelares Medical Centre, Ghent, Belgium, 7UZ Brussel, Vrije Universiteit Brussel, Brussels, Belgium, 8Ziekenhuis Oost Limburg, Genk, Belgium, 9Onze-Lieve-Vrouwziekenhuis, Aalst, Belgium, 10University Hospitals Leuven, Leuven, Belgium, 11AZ Groeninge Hospital, Kortrijk, Belgium, 12AZ St Lucas, Gent, Belgium, 13Hopital Universitaire Erasme, Brussels, Belgium, 14Clinique St-Pierre, Ottignies, Belgium, 15CHU UCL Namur site Sainte Elisabeth, Brussels, Belgium, 16AZ Delta, Roeselare, Belgium, 17Hospital CHR de la Citadelle, Liège, Belgium, 18Jessa Ziekenhuis, Hasselt, Belgium, 19CHU Ambroise-Paré, Mons, Belgium, 20Takeda Pharmaceuticals, Medical Affairs, Brussels, Belgium, 21Takeda Pharmaceuticals Company, Statistics, Boston, USA, 22Takeda Pharmaceuticals, Epidemiology, London, UK

P132: Detection and monitoring of IBD based on faecal volatile organic compounds

ECCO '19 Copenhagen

Year: 2019
Authors:

S. Bosch*1, D. Wintjens2, A. Wicaksono3, J. Kuijvenhoven4, P. Stokkers5, R. van der Hulst4, E. Daulton3, M. Pierik2, J. A. Covington3, N. K. De Boer1, T. G. de Meij6

1Amsterdam UMC, Gastroenterology and Hepatology, Amsterdam, The Netherlands, 2MUMC+, Gastroenterology and Hepatology, Maastricht, The Netherlands, 3University of Warwick, School of Engineering, Coventry, UK, 4Spaarne Gasthuis, Gastroenterology and Hepatology, Hoofddorp, The Netherlands, 5OLVG West, Gastroenterology and Hepatology, Amsterdam, The Netherlands, 6Amsterdam UMC, Pediatric gastroenterology, Amsterdam, The Netherlands

P133: Comparison of accuracy between faecal immunochemical test and faecal calprotectin for predicting mucosal healing in quiescent ulcerative colitis patients: a prospective multi-centre study

ECCO '19 Copenhagen

Year: 2019
Authors:

E. S. Kim*1, S. K. Kim1, H. S. Lee1, Y. J. Lee2, E. Y. Kim3, B. I. Jang4, K. O. Kim4, C. H. Yang5, Y-J. Lee1, E. Y. Lee1, Crohn’s and Colitis Association in Daegu-Gyeongbuk (CCAiD)1

1Kyungpook National University, School of Medicine, Internal Medicine, Daegu, South Korea, 2Keimyung University, School of Medicine, Internal Medicine, Daegu, South Korea, 3Catholic University of Daegu, School of Medicine, Internal Medicine, Daegu, South Korea, 4Yeungnam University College of Medicine, Internal Medicine, Daegu, South Korea, 5Dongguk University School of Medicine, Internal Medicine, Gyeongju, South Korea

P134: Long-term bowel function and fate of the ileal pouch after restorative proctocolectomy in patients with Crohn’s disease: a systematic review and meta-analysis

ECCO '19 Copenhagen

Year: 2019
Authors:

G. Pellino*1, D. Vinci1, G. Signoriello2, C. Kontovounisios3, S. Canonico1, F. Selvaggi1, G. Sciaudone1

1Universitá della Campania, Colorectal Surgery, Department of Medical, Surgical, Neurological, Metabolic and Ageing Sciences, Naples, Italy, 2Università della Campania Luigi Vanvitelli, Section of Statistic, Department of Mental Health and Public Medicine, Naples, Italy, 3Royal Marsden Hospital and Imperial College London, Unit of Colorectal Surgery, Royal Marsden Hospital, London, UK

P135: Altered body composition profiles in young adults with childhood-onset inflammatory bowel disease

ECCO '19 Copenhagen

Year: 2019
Authors:

G. V. Sigurdsson*1,2, S. Schmidt3, D. Mellström4, M. Karlsson5, M. Lorentzon6,7, R. Saalman1,2

1Queen Silvia′s Children Hospital, Gothenburg, Sweden, 2Institute of Clinical Sciences, The Sahlgrenska Academy at University of Gothenburg, Department of pediatrics, Gothenburg, Sweden, 3Premier Research LLC, Durham/NC, USA, 4Institute of Medicine, The Sahlgrenska Academy at University of Gothenburg, Centre for Bone and Arthritis Research, Department of Internal Medicine and Clinical Nutrition, Gothenburg, Sweden, 5Clinical and Molecular Osteoporosis Research Unit, Department of Clinical Sciences and Orthopedics, University of Lund, Malmö, Sweden, 6Institute of Medicine, The Sahlgrenska Academy at University of Gothenburg, Geriatric Medicine, Department of Internal Medicine and Clinical Nutrition, Gothenburg, Sweden, 7Sahlgrenska University Hospital, Geriatric Medicine, Gothenburg, Sweden

P136: Association between histological indices and ulcerative colitis activity measures among patients in the HICKORY (etrolizumab) open-label induction cohort

ECCO '19 Copenhagen

Year: 2019
Authors:

L. Peyrin-Biroulet*1, B. Feagan2, R. K. Pai3, U. Arulmani4, A. Boruvka5, Y. S. Oh4, A. Scherl4, A. Scalori5, P. Arrisi5, S. Tole4, D. T. Rubin6

1Université de Lorraine, Vandœuvre-lès-Nancy (Nancy University Hospital, Lorraine University), Nancy, France, 2University of Western Ontario, London, Canada, 3Mayo Clinic, Phoenix, USA, 4Genentech, South San Francisco, USA, 5Roche, Burgess Hill, UK, 6University of Chicago Medicine, Chicago, USA

P137: Serum biomarkers of degradation and formation of type III, IV and V collagen are associated with disease activity in patients with Crohn’s disease

ECCO '19 Copenhagen

Year: 2019
Authors:

V. Domislovic*1, J. H. Mortensen2, M. A. Karsdal2, A. Barisic1, T. Manon-Jensen2, Z. Krznaric1,3,4

1Clinical Hospital Centre Zagreb, Department of Gastroenterology and Hepatology, Zagreb, Croatia, 2Nordic Bioscience A/S, Biomarkers and Research, Herlev, Denmark, 3Unit of Clinical Nutrition, University Hospital Zagreb, Zagreb, Croatia, 4University of Zagreb, School of Medicine, Zagreb, Croatia

P138: Prediction model to safely cease anti-TNF therapy in Crohn’s disease: individual patient data meta-analysis (IPD-MA)

ECCO '19 Copenhagen

Year: 2019
Authors:

R. W. M. Pauwels*1, C. J. van der Woude1, D. Nieboer2, E. W. Steyerberg2,3, M. J. Casanova4, J. P. Gisbert4, A. J. Lobo5, C. W. Lees6, N. A. Kennedy5, T. Molnár7, K. Szánto7, E. Louis8, J-Y. Mary9, M. Lukas10,11, M. Duijvestein12, S. Bots12, G. R. A. M. D'Haens12, A. C. de Vries1

1Erasmus MC, Department of Gastroenterology and Hepatology, Rotterdam, The Netherlands, 2Erasmus MC, Department of Public Health, Rotterdam, The Netherlands, 3Leiden UMC, Department of Clinical Biostatistics and Medical Decision Making, Leiden, The Netherlands, 4Madrid Hospital Universitario de la Princesa, Instituto de Investigación Sanitaria Princesa (IIS-IP) and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Department of Gastroenterology, Madrid, Spain, 5Royal Hallamshire Hospital, Sheffield Teaching Hospitals NHS Foundation Trust, Department of Gastroenterology and Hepatology, Sheffield, UK, 6Western General Hospital, Department of Gastroenterology and Hepatology, Edinburgh, UK, 7University of Szeged, Department of Medicine, Szeged, Hungary, 8Centre Hospitalier Universitaire de Liège, Department of Gastroenterology and Hepatology, Liège, Belgium, 9INSERM U717, Department of Biostatistics and Clinical Epidemiology, Paris, France, 10IBD Clinical and Research Centre, Iscare a.s, Prague, Czech Republic, 11Institute of Medical Biochemistry and Laboratory Diagnostics, 1st Medical Faculty and General Teaching Hospital, Prague, Czech Republic, 12Amsterdam UMC, Academic Medical Centre, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands

P139: Advance of medical therapies may improve outcome of ulcerative colitis with cytomegalovirus infection

ECCO '19 Copenhagen

Year: 2019
Authors:

H. Kitamoto*1, S. Yamamoto1, M. Matsuura1, Y. Honzawa1, S. Yamada1, M. Okabe1, H. Seno1

1Graduate School of Medicine, Kyoto University, Department of Gastroenterology and Hepatology, Kyoto, Japan

P140: Challenges in colonoscopic surveillance in chronic IBD

ECCO '19 Copenhagen

Year: 2019
Authors:

S-L. Gillespie*1, N. Singh-Clark2, A. Shand1, C. Lees1, I. Arnott1, G-T. Ho1, E. Watson1, C. Noble1, S. Din1

1Edinburgh IBD Unit, Western General Hospital, Edinburgh, UK, 2University of Edinburgh, Edinburgh, UK

P141: Faecal calprotectin correlates to UCEIS and can predict short-term recurrence in patients with ulcerative colitis

ECCO '19 Copenhagen

Year: 2019
Authors:

M. Naganuma*1, T. Kobayashi2, T. Kanai1

1Division of Gastroenterology and Hepatology, Keio University, Tokyo, Japan, 2Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital, Tokyo, Japan

P142: Ulcerative colitis: risk factors for relapse in clinical remission patients

ECCO '19 Copenhagen

Year: 2019
Authors:

C. Arieira*1,2,3, H. Guimarães2, F. Dias de Castro1,2,3, M. J. Moreira1,2,3, J. Cotter1,2,3

1Hospital da Senhora da Oliveira, Gastroenterology, Guimarães, Portugal, 2Life and Health Sciences Research Institute, School of Medicine, University of Minho, Braga/Guimarães, Portugal, 3ICVS/3B’s, PT Government Associate Laboratory, Braga/Guimarães, Portugal

P143: Measuring the mediating effects of tofacitinib on health status in ulcerative colitis: data from the OCTAVE programme

ECCO '19 Copenhagen

Year: 2019
Authors:

M. Dubinsky1, A. Bushmakin2, M. DiBonaventura3, J. Cappelleri4, L. Salese5, E. Maller5, A. Armuzzi*6

1Mount Sinai, New York, USA, 2Pfizer Inc., New York, USA, 3Pfizer Inc., Patient and Health Impact, New York, USA, 4Pfizer Inc., Groton, USA, 5Pfizer Inc., Collegeville, USA, 6Fondazione Policlinico Gemelli IRCCS – Università Cattolica del Sacro Cuore, Rome, Italy

P144: Correlation between clinical, endoscopic, histological activity scores in a cohort of patients with ulcerative colitis: a prospective study

ECCO '19 Copenhagen

Year: 2019
Authors:

B. Neri*1, S. Romeo1, F. Zorzi1, E. De Cristofaro1, E. Calabrese1, E. Grasso1, G. Palmieri2, L. Biancone1

1University of Rome 'Tor Vergata', Gastroenterology, Rome, Italy, 2University or Rome 'Tor Vergata', Anatomopathology, Rome, Italy

P145: Telephone straight-to-test (tSTT) improves early diagnosis of inflammatory bowel disease (IBD)

ECCO '19 Copenhagen

Year: 2019
Authors:

H. Htet*1, T. Mudege1, S. Hoque1

1Whipps Cross Hospital, Barts Health NHS Trust, London, UK

P146: Dysplasia Surveillance in inflammatory bowel disease—a cohort study

ECCO '19 Copenhagen

Year: 2019
Authors:

S. Saraiva*1, I. Rosa1, J. Moleiro1, J. Pereira da Silva1, R. Fonseca1, A. Dias Pereira1

1Instituto Português de Oncologia de Lisboa Francisco Gentil, Gastroenterology, Lisbon, Portugal

P147: Thromboembolic complications in patients with Inflammatory bowel disease predict poor prognosis: a large North Indian cohort study

ECCO '19 Copenhagen

Year: 2019
Authors:

S. Yadukrishna*1, V. Teja1, S. Kedia1, S. Jain1, P. Sahu1, S. Kumar1, G. Makharia1, V. Ahuja1

1All India Institute Of Medical Sciences, New Delhi, India

P148: Timing to surgery in symptomatic Crohn’s disease—patients perception

ECCO '19 Copenhagen

Year: 2019
Authors:

M. Moratal1, M. Marti-Gallostra*1, F. Vallribera1, E. Epín1

1Hospital Vall d'Hebron, Colorectal surgery, Barcelona, Spain

P149: Searching for bile acid malabsorption using serum fibroblast growth factor 19 (FGF19) and faecal bile acids in patients with inflammatory bowel diseases, microscopic colitis and irritable bowel syndrome

ECCO '19 Copenhagen

Year: 2019
Authors:

I. Lyutakov*1, R. Nakov1, V. Nakov1, B. Vladimirov1, A. Dimov2, B. Asenova3, M. Chetirska3, R. Vatcheva-Dobrevska3, P. Penchev1

1University Hospital ‘Tsaritsa Yoanna – ISUL’, Gastroenterology Clinic, Sofia, Bulgaria, 2University of National and World Economy, Department of Statistics and Econometrics, Sofia, Bulgaria, 3University Hospital ‘Tsaritsa Yoanna – ISUL’, Microbiology and Virology Department, Sofia, Bulgaria

P150: High adherence to surveillance guidelines in IBD results in low CRC and dysplasia rates, while rates of dysplasia and cancer are low before the suggested start of surveillance. Results from a tertiary IBD centre

ECCO '19 Copenhagen

Year: 2019
Authors:

K. Singh1, A. Al Khoury2, Z. Kurti3, L. Gonczi*3, J. Reinglas2, C. Verdon2, R. Kohen2, T. Bessissow2, W. Afif2, G. Wild2, E. Seidman2, A. Bitton2, P. Lakatos2

1McGill University Health Center, Department of Medicine, Montreal, Canada, 2McGill University Health Center, Division of Gastroenterology, Montreal, Canada, 3Semmelweis University, First Department of Internal Medicine, Budapest, Hungary

Page: () 1 ... 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 ... 182 ()